Trials / Recruiting
RecruitingNCT06214156
A Clinical Study of T3011 in Subjects With Advanced Melanoma
A Phase Ib/IIa Clinical Study to Evaluate the Tolerability, Safety and Preliminary Efficacy of T3011 in Subjects With Advanced Melanoma
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 42 (estimated)
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This clinical study evaluated the tolerability, safety and preliminary efficacy of T3011 in subjects with advanced melanoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | T3011 | T3011 will be given intratumorally， Q2W； |
Timeline
- Start date
- 2024-01-26
- Primary completion
- 2026-09-30
- Completion
- 2026-09-30
- First posted
- 2024-01-19
- Last updated
- 2026-01-14
Locations
7 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06214156. Inclusion in this directory is not an endorsement.